JANX vs MESO: fair value comparison
Janux Therapeutics, Inc. and Mesoblast Limited · Updated 2026-10-19
JANX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MESO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, JANX currently ranks higher by quality score.
| JANX | MESO | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $16.51 | $13.28 |
| 12-month range | $12.18–$34.74 | $13.19–$20.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #104 of 301 Healthcare | #105 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: JANX fair value analysis · MESO fair value analysis